Schering Ag Articles

First EU approval for Schering AG's Nebido

15 December 2003

Schering AG signs Australian deal

8 December 2003

Schering AG's contrast agent appro for MRA

8 December 2003

Stock Commentary - Europe

24 November 2003

Stock Commentary - Europe

10 November 2003

Astex boosts cash with MetaGen acquisition

10 November 2003

Schering AG/IBC deal on cancer therapy

3 November 2003

Stock Commentary - Europe

3 November 2003

Schering AG sees strong profit growth

3 November 2003

New wave of drugs offer hope in treatment of colon cancer

3 November 2003

Schering AG licenses Ventavis US rights

27 October 2003

FDA clears Betaferon pre-filled diluent syringe

20 October 2003

Stock Commentary - Europe

20 October 2003

Positive Phase II results for Schering AG's Leukine as a Crohn's disease therapy

20 October 2003

Indian pharmaceutical news in brief

13 October 2003

Amersham confirms bid approach; shares leap to 18-month high

13 October 2003

Schering AG's Zevalin gets positive opinion

6 October 2003

Reform to cost German pharma "$950M-plus"

29 September 2003

Schering AG establishes new research center in Japan

29 September 2003

Schering AG's gets EU appro for Ventavis

29 September 2003

Boeh Ing implores Germany to rewaed innovation after $285M R&D expansion

29 September 2003

Boeh Ingelheim opens new 255M-euro facility

22 September 2003

Stock Commentary - Europe

15 September 2003

German health reform "will cost pharma close to 3B euros in 2004," says VFA

8 September 2003

Appointments and departures at Nihon Schering

11 August 2003

Stock Commentary - Europe

11 August 2003

Altana on track as field force spend increases

11 August 2003

German management now moving to USA

11 August 2003

Profits and sales down at Schering AG

11 August 2003

Schering AG's Leukine may compensate for Yasmin generics, says Morgan Stanley

4 August 2003

Berlex selects Fast Track Systems for clinical trials

4 August 2003

Galen Merger talks terminated

28 July 2003

Stock Commentary - Tokyo

28 July 2003

Stock Commentary - Europe

28 July 2003

UPDATE: Galen merger talks with Barr terminated as share price is driven higher

28 July 2003

Tokyo pharma stocks - week to July 21

28 July 2003

Schering AG' Ph III MS-325 trial complete

21 July 2003

Marc Rubin joins Schering AG supervisory board

14 July 2003

Schering AG's R&D day impressive, but doubts over short term, say analysts

7 July 2003

Stock Commentary - Europe

7 July 2003

Stock Commentary - Europe

30 June 2003

LION Bioscience names Klaus Pohle to supervisory board

30 June 2003

Cytogen reacquires rights to pain product

23 June 2003

Schering AG enters deals with EPIX and Astex

2 June 2003

Schering AG gets CPMP OK for Ventavis

2 June 2003

Stock Commentary - Europe

12 May 2003

lPromotions at Berlex Labs

12 May 2003

Schering AG and Astex enter drug discovery collaboration

12 May 2003

Nihon Schering names Gunter Stock as chairman

5 May 2003

Italy's Chiesi sees flat sales in 2002

28 April 2003

Gedeon Richter sees product mix improve in 2002

21 April 2003

Stock Commentary - Europe

21 April 2003

CompleGen and Berlex sign discovery deal

14 April 2003

Scheirng AG gets favorable S&P's/Moody's rating

14 April 2003

Berlex launches rosacea gel in USA

31 March 2003

Stock Commentary - Europe

24 March 2003

Expanded US label OKed for Betaferon

24 March 2003

EPIX' MS-325 clears second Ph III trial in MRA

17 March 2003

Ilex may extend Campath license with BTG

10 March 2003

Update: Sales up 11% at Schering AG

10 March 2003

Schering AG beats forecasts in 2002

10 March 2003

Biogen's earnings lower following court ruling

3 March 2003

Stock Commentary - Week to Feb 17 - Europe

24 February 2003

Autoinjector for Betaferon launched in Germany

24 February 2003

Study questions long-term IFN use in MS

24 February 2003

Stock commentary - week to Feb 10 - Europe

17 February 2003

Fludara cleared for first-line use in CLL

17 February 2003

Stock Commentary - Europe

10 February 2003

Biogen to pay $55M to Schering AG

10 February 2003

Schering AG's 2002 sales disappoint

10 February 2003

Round-up of pharmaceutical mergers and acquisitions during 2001

13 January 2003

Schering AG in cancer diagnostic alliance with Peregrine

13 January 2003

Schering AG in accord with USA's Valentis

6 January 2003

Berlex gets OK for rosacea treatment in USA

6 January 2003

D&TB dismisses weight-neutral claims for Yasmin

19 August 2002

Stock Commentary - Europe

12 August 2002

Stock Commentary - Europe

5 August 2002

Schering AG US sales up 22% in Q2

5 August 2002

Pharmacopeia reaches Schering agreement milestone

5 August 2002

Stock Commentary - Europe

29 July 2002

Schering and Serono settle US patent dispute

29 July 2002

Stock Commentary - Europe

22 July 2002

Schering receives Austrian OK for Skinoren

22 July 2002

US FTC OKs Amgen/Immunex merger

22 July 2002

Prempro fall-out could affect Schering AG

22 July 2002

Pfizer's muscle to support Rebif in USA

15 July 2002

Wyeth hit as Prempro linked to cancer, CVD

15 July 2002

Schering aquires MAP

15 July 2002

MorphoSys looking for new investors to achieve greater independence for products

15 July 2002

Italy

15 July 2002

Schering and Collateral complete merger

8 July 2002

Schering AG gets Euro Testogel rights

8 July 2002

Schering AG and Neurosciences form research partnership

8 July 2002

EU launch of NHL drug Zevalin delayed

8 July 2002

Schering AG starts trial to compare Betaferon and Copaxone

8 July 2002

Schering AG enters neurodegenerative JV with NSV

1 July 2002

Pharmion to market Refludan outside the USA and Canada

10 June 2002

MediGene completes enrollment in cervical cancer trial

13 May 2002

Stock Commentary - Europe

13 May 2002

Stock Commentary - New York

13 May 2002

Showing 301-400 of 974 articles

Go to beginningPreviousNextGo to end